Ketamine for Migraine: How Off-Label Infusions Work
How ketamine is used off-label for refractory migraine and status migrainosus — evidence, dosing routes, safety, and who's a candidate in Boise and Eagle, ID. Ketamine for Migraine: How Off-Label Infusions Work Migraine that no longer responds to triptans, preventives, or infusions leaves people searching for anything else that might work — and ketamine keeps coming up. This guide explains how ketamine migraine care is actually used off-label in supervised clinics, what the published evidence does and doesn't support, how the delivery routes differ, and who gets screened in or out. No hype, no promises — just a clear look at a treatment that's still early in its headache story. Quick Answer Ketamine is not FDA-approved for migraine. It is used off-label in some specialty headache and infusion clinics for refractory migraine, status migrainosus (a severe attack lasting more than 72 hours), and chronic migraine with central sensitization. The two routes studied most are low-dose intravenous (IV) infusion and intranasal ketamine. The published evidence is early-stage — mostly small studies and hospital case series — so candidacy is decided case by case with a clinician. TL;DR Ketamine has no FDA approval for headache disorders. Its approved use is as an anesthetic, and off-label prescribing is a normal, legal part of medicine. See how off-label status is explained The proposed mechanism is NMDA receptor blockade , the same glutamate pathway tied to central sensitization and wind-up pain. Read the mechanism walkthrough The research base is small and mixed , with the strongest signals in refractory, hospital-treated cases rather than everyday attacks. Review what the studies actually support IV and intranasal routes differ in setting, monitoring, and maturity of evidence — and Spravato is approved for depression, not migraine. Compare the delivery routes side by side Screening matters more than enthusiasm : blood pressure, cardiac, bladder, psychiatric, and substance-use history all factor in. Check the candidacy criteria In This Article Why Do Some Migraines Stop Responding to Standard Treatment? How Does Ketamine Work on Migraine Pain? What Does the Research Actually Show? IV Ketamine vs. Intranasal Ketamine for Migraine Who Is a Candidate for Off-Label Ketamine for Migraine? What Happens During a Ketamine Infusion Session? How Does Ketamine Compare to IV Hydration and Magnesium? What Are the Risks and Realistic Expectations? Why Do Some Migraines Stop Responding to Standard Treatment? Repeated pain signaling can leave the nervous system in a heightened, self-sustaining state that abortive medications were never designed to reverse. That state has a name. Central sensitization is an amplified response of central nervous system neurons to normal or mildly painful input. In migraine, clinicians often see it as cutaneous allodynia — when brushing your hair, wearing glasses, or a light touch on the scalp starts to hurt during an attack. Most people work through the standard ladder first: Abortives — triptans and newer gepants such as ubrogepant or rimegepant CGRP monoclonal antibodies — preventives like erenumab or galcanezumab Onabotulinumtoxin A injections — used for chronic migraine Older preventives — topiramate, beta blockers, tricyclics, anti-nausea support When several of those classes have been tried without adequate benefit, the headache is often described as refractory — resistant to standard care. A smaller group progresses toward near-daily headache, where attacks blur together and the line between "attack" and "baseline" disappears. ⚠️ Caution: Frequent use of acute medications can contribute to medication-overuse headache, which can look identical to worsening migraine. Any escalation in painkiller frequency deserves a review with your prescriber before adding another treatment on top. For Boise and Eagle readers in this position, the useful first step is a structured migraine treatment consultation that maps what's been tried, what worked partially, and what was stopped for side effects. Key takeaway: Refractory migraine isn't a willpower problem — it reflects a sensitized pain system that standard abortives target only indirectly. How Does Ketamine Work on Migraine Pain? Ketamine blocks the NMDA glutamate receptor, the receptor most implicated in maintaining central sensitization. An NMDA receptor antagonist is a drug that blocks glutamate signaling at the N-methyl-D-aspartate receptor. Ketamine is described in the clinical literature primarily as an NMDA antagonist with dissociative anesthetic properties ( StatPearls, NCBI Bookshelf ). The proposed chain in headache medicine looks like this: Repeated pain input drives glutamate release in the spinal trigeminal nucleus. NMDA receptors activate and stay primed. Neurons "wind up" — the same input produces a bigger pain response. Allodynia and daily background headache set in. Blocking NMDA signaling is theorized to interrupt that loop. What makes the ketamine migraine approach different from standard abortives? Triptans and gepants act on the vascular and CGRP side of an attack. The ketamine migraine hypothesis targets the amplification itself — the reason a nervous system keeps generating pain after the trigger has passed. That's a different job, which is why it's considered mainly for people whose attacks have already outlasted conventional options. If you want the neuroscience in more depth, our explainer on how ketamine works on the brain covers glutamate signaling and neuroplasticity in plain language. Key takeaway: The mechanism is plausible and well-described in pharmacology, but a plausible mechanism is not the same as proven headache benefit. What Does the Research Actually Show? The honest summary: the evidence base for ketamine in migraine is small, early, and mixed. Published work has largely come from open-label studies, retrospective hospital series in patients with severe refractory headache, and a smaller number of controlled trials in emergency settings. Results have not been uniform — some reports describe improvement in difficult cases, while controlled acute-care research has been less encouraging. What that means for you as a reader: No regulatory approval exists for ketamine as a migraine treatment in the United States. No standardized protocol exists for headache — dose, duration, and series length vary between clinicians. No one can quote a reliable success rate for migraine, because the trials large enough to produce one haven't been done. Individual results vary , and suitability is determined in a clinical consultation, not from an article. Be skeptical of any clinic — ours included — that presents ketamine for headache as settled science. What is well documented is ketamine's pharmacology, its adverse-effect profile, and the monitoring it requires ( StatPearls ). Everything about headache-specific outcomes remains an active research question. For practical questions about cost, screening, and how sessions are supervised, our ketamine safety and process FAQ covers the operational side. Key takeaway: Treat off-label ketamine for migraine as an option to discuss after standard care has been exhausted — not as a first move or a guaranteed answer. IV Ketamine vs. Intranasal Ketamine for Migraine: What's the Difference? IV infusion offers controlled dosing and continuous monitoring in a clinical setting, while intranasal ketamine has been studied more as a self-administered adjunct. A third product, esketamine (Spravato), is frequently confused with both — and it is approved for depression, not headache. Feature IV subanesthetic infusion Intranasal ketamine (compounded) Esketamine (Spravato) Setting In-clinic, supervised Studied for at-home/adjunct use Certified healthcare setting under a REMS program Dose control Precise, adjustable during session Variable absorption Fixed device doses per label Monitoring Continuous vitals, clinician present Minimal by design Post-dose monitoring required by label Approved for migraine? No — off-label No — off-label No — labeled for treatment-resistant depression and depressive symptoms in adults with MDD with acute suicidal ideation or behavior Evidence maturity for headache Early, mostly refractory/inpatient reports Early, small open-label work Not indicated for headache Practical drawbacks Time commitment, no driving after, self-pay Absorption variability, less oversight Restricted distribution; not a headache therapy ⚠️ Important distinction: Spravato's FDA labeling covers depression indications only and requires administration under a restricted program ( FDA prescribing information ). Any clinic implying Spravato is a migraine treatment is misrepresenting the label. For refractory headache, the supervised route is where monitoring, dose adjustment, and immediate clinician response are possible — which is how IV ketamine therapy in Eagle and Boise is structured. The trade-off is time, cost, and the need for a ride home. Who Is a Candidate for Off-Label Ketamine for Migraine? Generally, adults with chronic or refractory migraine who have already tried multiple preventive and abortive classes without adequate benefit — and who clear medical screening. A candidacy screen is a structured review of your diagnosis, treatment history, and medical risk factors before any infusion is offered. Typical items include: Confirmed headache diagnosis from a clinician or neurologist, not self-diagnosis Two or more failed preventive medications , documented A headache diary showing attack frequency, duration, and triggers Blood pressure within a safe range — ketamine can transiently raise blood pressure No active psychosis or unmanaged bipolar mania No untreated substance use disorder involving dissociatives or stimulants No history of interstitial cystitis or unexplained bladder symptoms — a specific screening flag A confirmed ride home and no driving for the remainder of the day Cardiac history, uncontrolled hypertension, pregnancy, and certain medication interactions are all reasons a clinician may decline or defer. Ketamine's contraindications and monitoring requirements are well described in the clinical literature ( StatPearls ). Many people with refractory migraine also carry overlapping pain conditions — neck pain, fibromyalgia, or widespread sensitization. If that describes you, a chronic pain treatment consultation may be the more appropriate starting conversation. What Happens During a Ketamine Infusion Session? A subanesthetic infusion used for pain generally runs at a lower dose over a longer window than a depression protocol, with vitals monitored throughout. The visit sequence typically looks like this: Intake and vitals — blood pressure, heart rate, and a check on medications and food/fluid intake IV placement by the clinician The infusion , commonly 40–60 minutes or longer for pain protocols, with the rate adjustable Dissociative effects — a floating, dreamlike, or detached feeling that is expected and time-limited Anti-nausea support — an antiemetic such as ondansetron is commonly given alongside Recovery window of roughly 30 minutes before discharge to your driver No driving, machinery, or important decisions for the rest of the day Sessions are usually planned as a short series rather than a one-off visit, with spacing and any maintenance decided by your clinician based on how you respond and tolerate it. Because there's no universal migraine protocol, expect the plan to be individualized — and expect it to be revisited. Our step-by-step page on what to expect from IV ketamine walks through preparation, the room setup, and aftercare in more detail. How Does Ketamine Compare to IV Hydration and Magnesium for Migraine? They solve different problems. Nutrient and hydration infusions address fluid loss, magnesium levels, and the depleted feeling after a long attack. Ketamine targets sensitized pain signaling itself. Approach Primary goal What's delivere